Suppr超能文献

利用日本药品不良事件报告数据库对激酶抑制相关不良事件进行可视化分析。

Visualization of Kinase Inhibition-Related Adverse Events Using the Japanese Adverse Drug Event Report Database.

作者信息

Mizuno Takahito, Sakai Takamasa, Tanabe Kouichi, Umemura Takumi, Goto Nobuyuki, Ohtsu Fumiko

机构信息

Department of Pharmacy, Tosei General Hospital, 160-Nishioiwake-cho, Seto, Aichi, 489-8642, Japan.

Graduate School of Pharmacy, Meijo University, Aichi, Japan.

出版信息

Drugs Real World Outcomes. 2021 Jun;8(2):197-206. doi: 10.1007/s40801-021-00235-w. Epub 2021 Mar 9.

Abstract

INTRODUCTION

Small molecule tyrosine kinase inhibitors (TKIs) inhibit not only the target kinase but also various kinases as off-target inhibitors not mentioned in the package insert. However, there are no reports that comprehensively examine the relationship between adverse events and kinase affinity.

OBJECTIVE

In this study, we combined basic data and clinical data to visualize the relationship between kinase affinity and adverse events, which will be useful for the management of adverse events in clinical practice.

METHODS

We targeted TKIs that have been used domestically and for which the dissociation constant was obtained as reported by Davis et al. Adverse event data recorded in the Japanese Adverse Drug Event Report (JADER) database provided by the Pharmaceuticals and Medical Devices Agency between April 2004 and January 2018 were used. We calculated the reporting rates of the Standardized MedDRA Queries (SMQ) for the adverse events of interest and visualized the correlation coefficients with kinase affinity. We used the adverse events associated with VEGFR2 and EGFR to assess their validity.

RESULTS

We found a correlation among known kinase-related adverse events, suggesting that the methodology may be used as a signal detection method to generate hypotheses for clinical and basic research.

CONCLUSION

Our comprehensive analysis of the kinase affinity of TKIs in this study, which was based on basic TKI kinase affinity data and the clinical data of the reporting rates, suggested that our comprehensive analysis method is useful for generating hypotheses about possible causal relationships between pharmacological effects and adverse events.

摘要

引言

小分子酪氨酸激酶抑制剂(TKIs)不仅能抑制靶激酶,还能作为未在药品说明书中提及的脱靶抑制剂抑制多种激酶。然而,尚无全面研究不良事件与激酶亲和力之间关系的报道。

目的

在本研究中,我们将基础数据与临床数据相结合,以直观呈现激酶亲和力与不良事件之间的关系,这将有助于临床实践中不良事件的管理。

方法

我们选取了在国内使用且如Davis等人报道那样获得解离常数的TKIs。使用了药品和医疗器械局提供的2004年4月至2018年1月期间日本药品不良事件报告(JADER)数据库中记录的不良事件数据。我们计算了感兴趣的不良事件的标准化医学术语词典查询(SMQ)报告率,并直观呈现与激酶亲和力的相关系数。我们使用与血管内皮生长因子受体2(VEGFR2)和表皮生长因子受体(EGFR)相关的不良事件来评估其有效性。

结果

我们发现了已知的激酶相关不良事件之间的相关性,表明该方法可用作信号检测方法,为临床和基础研究生成假设。

结论

我们在本研究中基于TKI激酶亲和力基础数据和报告率临床数据对TKIs激酶亲和力进行的综合分析表明,我们的综合分析方法有助于生成关于药理作用与不良事件之间可能因果关系的假设。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d72e/8128962/cf7809b0f193/40801_2021_235_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验